Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Amortizatization of Intangibles (2016 - 2025)

Historic Amortizatization of Intangibles for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $704000.0.

  • Ultragenyx Pharmaceutical's Amortizatization of Intangibles fell 7739.97% to $704000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year decrease of 5430.77%. This contributed to the annual value of $12.6 million for FY2024, which is 169.76% down from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Amortizatization of Intangibles stood at $704000.0 for Q3 2025, which was down 7739.97% from $1.0 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Amortizatization of Intangibles' 5-year high stood at $3.9 million during Q4 2023, with a 5-year trough of -$2.1 million in Q4 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $1.6 million (2022), whereas its average is $1.0 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Amortizatization of Intangibles plummeted by 94733.33% in 2021 and then skyrocketed by 37667.7% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Amortizatization of Intangibles (Quarter) stood at -$2.1 million in 2021, then soared by 178.31% to $1.6 million in 2022, then skyrocketed by 139.27% to $3.9 million in 2023, then dropped by 28.93% to $2.8 million in 2024, then crashed by 74.91% to $704000.0 in 2025.
  • Its last three reported values are $704000.0 in Q3 2025, $1.0 million for Q2 2025, and $1.7 million during Q1 2025.